Huperzine A

Huperzine A binds reversibly to acetylcholinesterase and blocks it from degrading acetylcholine in the synapse, raising acetylcholine levels in the brain. This is the same mechanism as the approved Alzheimer's drugs donepezil, rivastigmine, and galantamine, and huperzine A is more selective for brain acetylcholinesterase over the peripheral butyrylcholinesterase, which may reduce some side effects. It crosses the blood-brain barrier efficiently and has a long duration of action (half-life around 10–14 hours). Beyond cholinesterase inhibition, laboratory studies show it blocks NMDA glutamate receptors (reducing excitotoxicity), protects neurons from beta-amyloid toxicity and oxidative stress, supports mitochondrial function, and increases nerve growth factor, though the clinical relevance of these secondary effects is unknown.

Most research comes from China. A 2008 Cochrane review identified six RCTs of huperzine A in Alzheimer's disease (454 patients) and concluded it appeared to improve cognition, global function, behavior, and daily living, but that all trials were small, short, and of poor methodological quality, so no firm conclusion could be drawn. A 2013 meta-analysis of 20 trials with 1,823 participants reached a similar positive conclusion with the same caveats. The one rigorous Western trial — a 2011 US phase II study of 210 people with mild to moderate Alzheimer's — found that 200 mcg twice daily did not improve cognition versus placebo over 16 weeks, while 400 mcg twice daily produced a modest, statistically significant improvement on the ADAS-Cog scale but not on other measures. Smaller Chinese trials report benefits in vascular dementia and in adolescent students, but these have serious design limitations. Studies in healthy adults for nootropic purposes are essentially nonexistent. The evidence is moderate in quantity but low in quality, and the compound should be regarded pharmacologically as a drug rather than a gentle herbal supplement.

Huperzine A (a sesquiterpene alkaloid); purified or synthesized for supplements, often standardized from Huperzia serrata extract

Huperzine A is rapidly and almost completely absorbed after oral dosing, reaching peak blood levels within about an hour and crossing readily into the brain. Its elimination half-life of roughly 10–14 hours is long compared with other cholinesterase inhibitors, so once-daily dosing provides sustained enzyme inhibition and daily use can lead to accumulation. This long action is why many users take breaks or cycle it. Food does not markedly affect absorption. The drug is cleared mainly by the kidneys, so impaired kidney function may prolong its effects.